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STUDY PROTOCOL Open Access
Reactive community-based self-
administered treatment against residual
malaria transmission: study protocol for
a randomized controlled trial
Joseph Okebe1 , Joan Muela Ribera2, Julie Balen3, Fatou Jaiteh1,4,5, Yoriko Masunaga4,5, Davis Nwakanma1,
John Bradley6, Shunmay Yeung7, Koen Peeters Grietens4 and Umberto D’Alessandro1,8*
Abstract
Background: Systematic treatment of all individuals living in the same compound of a clinical malaria case may
clear asymptomatic infections and possibly reduce malaria transmission, where this is focal. High and sustained
coverage is extremely important and requires active community engagement. This study explores a community-
based approach to treating malaria case contacts.
Methods/design: This is a cluster-randomized trial to determine whether, in low-transmission areas, treating
individuals living in the same compound of a clinical malaria case with dihydroartemisinin-piperaquine can reduce
parasite carriage and thus residual malaria transmission. Treatment will be administered through the local health
system with the approach of encouraging community participation designed and monitored through formative
research. The trial goal is to show that this approach can reduce in intervention villages the prevalence of
Plasmodium falciparum infection toward the end of the malaria transmission season.
Discussion: Adherence and cooperation of the local communities are critical for the success of mass treatment
campaigns aimed at reducing malaria transmission. By exploring community perceptions of the changing trends in
malaria burden, existing health systems, and reaction to self-administered treatment, this study will develop and
adapt a model for community engagement toward malaria elimination that is cost-effective and fits within the
existing health system.
Trial registration: Clinical trials.gov, NCT02878200. Registered on 25 August 2016.
Keywords: Reactive case treatment, Community, Plasmodium falciparum, Formative research, Prevalence
Background
There is growing interest in mass drug administration
(MDA) of at-risk populations with an effective antimal-
arial as a means to reduce the human reservoir of infec-
tion [1]. MDA aims to provide full treatment courses to
the whole population to clear asymptomatic infections
and provide posttreatment prophylaxis to prevent re-
infection. It has been used effectively in the control and
elimination of diseases such as trachoma and in emer-
gencies such as malaria epidemics. The use of MDA is
recommended in areas approaching interruption of
transmission; with good access to treatment, effective
vector control, and surveillance systems; and having a
minimal risk of reintroduction of infection [2]. MDAs
have been conducted using a variety of drug regimens at
different dosages, timings, and frequencies. These show
substantial but short-lived reduction in Plasmodium
falciparum parasite carriage [3]. With the growing
awareness of heterogeneity and clustering in transmis-
sion, MDA approaches have been modified by systematic
(mass screening and treatment) or focused (focal
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screening and treatment) screening and treatment of
populations. Reactive case detection (i.e., screening treat-
ing positive contacts in response to a clinical event) has
been tested [4, 5] and implemented in some countries
[6, 7]. However, its impact has been variable [8, 9] be-
cause it is affected by the sensitivity of the diagnostic
tool and the radius of intervention around a clinical case
[10, 11]. These programs require strong coordination
and often lack community engagement.
Malaria transmission in The Gambia is seasonal, oc-
curring during and immediately after the rainy season
(July–December), and has decreased significantly over
the past decade [12, 13]. Key interventions that have led
to this decline are case management with artemisinin-
based combination therapy (ACT) and the use of long-
lasting insecticidal nets (LLINs) [14]. Malaria case
management involves screening suspected cases, mostly
by a rapid diagnostic test (RDT), and treatment of posi-
tive cases with artemether-lumefantrine. This service is
available at all public health facilities and from village
health workers (VHWs) at the community level. VHWs
are volunteers identified by their communities, trained
by the government, and provided with RDTs and
artemether-lumefantrine.
As malaria becomes uncommon, community engage-
ment is needed to help identify cases or treat asymptom-
atic infected individuals, and these steps depend on a
robust understanding of community perceptions of dis-
ease, infection, and transmission [15, 16]. The planned
study develops and implements a strategy for commu-
nity engagement to reduce malaria prevalence and thus
malaria transmission. Such an approach of reactive treat-
ment of clinical malaria cases’ contacts is developed
using a mixed methods approach to understanding how
communities perceive it and how it can be integrated
within the existing health system.
Trial objective
The objective of this trial is to determine whether ad-
ministering an antimalarial treatment to all individuals
living in the same compound of clinical malaria cases
would result in a lower prevalence of P. falciparum in-
fection at the village level.
Methods/design
This is a cluster-randomized trial designed to assess the
impact of reactive treatment of contacts of a clinical
malaria case living in the same compound on the preva-
lence of malaria infection at the end of the transmission
season. The trial is planned over two transmission sea-
sons. In the first (exploratory) season, villages are identi-
fied and approaches to integrate the intervention into
the community and health systems will be tested and
adapted by social scientists and health systems re-
searchers. The final portfolio of messages to support the
intervention will be applied in the second (implementa-
tion) season (Fig. 1).
Study setting
The study is being conducted in villages on the North Bank
of the River Gambia and covers an area of approximately
45 km west of the town of Farafenni. P. falciparum is re-
sponsible for nearly all malaria infections in The Gambia
[17]. Malaria transmission in this area has declined substan-
tially, with parasite prevalence of about 3% in a population
sampled during the peak of transmission [13]. It is therefore
an ideal location because the intervention is designed for
targeting residual clusters of transmission.
A village is composed of compounds, and each com-
pound is clearly defined by a fence. It is typically com-
posed of several buildings and rooms with different
functions that serve one or several households. Locally,
a household is defined as “all the people who eat from
the same bowl” and consists of members of an extended
patrilineal family. A typical compound has the men’s
house, where each adult male has his own room; the
women’s house, where the wives of all married men from
the household, their daughters, and children stay; the
kitchen; and the “boys’ house” for young circumcised
men. The decision to treat all individuals in a compound
was based on the need to cover as many individuals as
possible around the clinical case and also because of the
clear demarcation between compounds.
Village selection and consenting
Medium-sized villages (population ≥ 100) in the area
were targeted, and parasite prevalence by loop-mediated
Fig. 1 Timeline for project activities
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isothermal amplification (LAMP) assay was determined
[18] in January 2016. Villages of this size were targeted
because they are likely to have a resident VHW. Villages
with a parasite prevalence > 0.5% were included in the
trial and randomly assigned to an intervention or con-
trol arm using a computer-generated minimizing algo-
rithm (Fig. 2). A census was conducted in each village to
determine the population size and age structure. In
addition, weight measurements were documented for
residents in villages that made up the intervention arm.
Because all residents of the villages are potentially at
risk of infection and clinical malaria during the trans-
mission season, a written informed consent will be re-
quired from everyone before study-related activities are
implemented. To ease identification of compound mem-
bers, consent will be obtained preemptively before the
start of the malaria transmission season in all selected
villages. Consent for children will be provided by their
guardians, and those 12–17 years old will be asked to
provide an assent in addition to a written consent from
a responsible adult. This process will be updated in the
course of the trial, especially in compounds where new
residents have been added or individuals missed in the
earlier exercise are reported. A list of residents in the
study villages, by compound, including weight and con-
sent status, will be generated and made available to
study nurses at the local health facility and to VHWs in-
volved in the trial.
Activities in the intervention arm
Trial activities are initiated after an individual from a vil-
lage assigned to intervention is diagnosed with malaria
and treated at either a health facility or by a VHW with
artemether-lumefantrine. Individuals living in the same
compound as this index case will be identified from the
census logbook produced for the trial, with the help of
the patient or escort if the patient is a minor. A full
(3-day) course of dihydroartemisinin-piperaquine (DP),
dispensed on the basis of body weight, will be packed
for each individual in the compound for distribution. DP
is recommended for the treatment of uncomplicated P.
falciparum malaria [19], available in pediatric (dihy-
droartemisinin 20 mg/piperaquine 160 mg) and older
child/adult (dihydroartemisinin 40 mg/piperaquine 320
mg) tablet formulations, and administered as a once-
daily treatment.
Where the clinical case is identified at a health facility,
study nurses will hand treatment packs labeled with each
recipient’s name and dosing instructions to the escort to
take home. The study nurse informs the resident VHW
or village collaborator (VC)—a volunteer identified by
the community, if the village does not have a VHW—of
the event and the compound where treatment has been
sent. The VHW or VC then visits the compound on the
same day and helps distribute the medicines. If the mal-
aria case is detected by the VHW, he/she will visit the
compound and distribute prepacked medicines to resi-
dents of the compound following instructions on the
logbook developed in a way usable for VHWs. Follow-
up visits will be scheduled for the day after treatment
has been completed where the VHW or VC returns to
the compound to confirm that treatment was taken, re-
trieve empty or unused drug packets, and inquire about
any adverse events during the period. This information
will be relayed back to the study nurse. A field assistant
will collect any unused drugs and empty packets (Fig. 3).
Activities in the control arm
Activities in the control arm during the trial implementa-
tion period will be limited to observations of the routine
case management of malaria by either the VHW or the
health facility and measurement of the risk of infection in
the compound of an index case. Where an index case is
Fig. 2 Village selection and randomization into trial arms
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confirmed, it is reported to the study team that will visit
the compound and collect a fingerprick blood sample for
later detection of P. falciparum infection at the laboratory.
Members of the compound are not treated.
Eligibility and participation
The unique requirement for participation in the trial in-
forms the need for an adaptive approach in the study
design and defining eligibility. All residents in the inter-
vention villages are potentially eligible. However, reactive
treatment targets only compounds in the intervention
villages where a clinical malaria case occurs and treats
only compound members who are eligible at that time.
The key eligibility criteria for receiving treatment in-
clude residence in the study area for at least 1 month
during the transmission season, willingness to
Fig. 3 Schematic describing activities in the trial arms following identification of a malaria case
Fig. 4 Table showing schedule for enrollment, interventions, assessments, analysis, and dissemination of results
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participate, weight ≥ 5 kg, and no known history of heart
disease or allergies to DP; pregnant women are eligible
only after the first trimester. Eligibility of compound
members may change during the course of the trial
period, so it is essential to ensure comprehension and
maintain interest in the trial. For instance, pregnancy
(first trimester) and weight (≥ 5 kg) status need to be
confirmed at the time of treatment. Social scientists
involved with the trial will explore perceptions of treat-
ment for asymptomatic malaria infections and produce
information that provides clarity and context to the trial
activities, which will be shared with the communities
during the implementation phase.
In the control arm, only a blood sample from the com-
pound members will be collected. Therefore, the eligibil-
ity criteria are limited to residence in the study area for
at least 1 month during the transmission season and
willingness to participate.
Study outcomes
The primary endpoint is the prevalence of P. falciparum
malaria infection measured by molecular methods at the
end of the second year. Prevalence will be compared be-
tween intervention and control arms.
Secondary endpoints include the following:
 Prevalence of clinical (laboratory-confirmed) malaria
detected in study villages during the transmission
season
 Treatment coverage: the proportion of individuals in
each compound in the intervention arm that received
and took the prescribed dose
 Prevalence of antimalarial drug resistance molecular
markers and difference between study arms
 In the control arm, the proportion of infected
individuals at the time of a clinical event
Sample size calculation
The sample size calculation assumed reactive treatment
would result in a 60% difference in parasite prevalence
between the intervention and control arms in an area
with a prevalence around 5% [20]. A minimum of 16
villages per trial arm would be needed to detect such a
reduction between the intervention and control arms
with 80% power, a 5% significance level, and a coefficient
of variation of 0.7 [21].
Assignment of villages to trial arms
The unit of randomization is the village because the pri-
mary endpoint, malaria prevalence, is measured at this
level. Using the data from a baseline survey in which
blood samples were analyzed with a LAMP assay, the
trial statistician will randomize villages to one of the two
study arms using a computer-generated randomization
sequence. First, a minimization algorithm [22] based on
the imbalance measure by Raab and Butcher [23] will be
used to generate a series of optimal scenarios that adjust
for imbalances in prevalence between arms. Villages will
then be randomly allocated, using a two-block
randomization sequence, into two groups by selecting an
optimal sequence from the lot generated. This will be
done using Stata 14 software (StataCorp, College Station,
TX, USA). Blinding of interventions is not feasible, be-
cause both individuals taking the medicines and health
workers distributing them will be aware of who is receiv-
ing the intervention. However, samples collected during
the study will be assigned unique identifiers, and staff
processing samples will not be aware of the identity of
the individuals or their allocation arm.
Laboratory processes
Fingerprick blood samples collected on filter papers dur-
ing the prevalence surveys and compound screening will
be tested for P. falciparum infection by using a qPCR
assay targeting the var gene acidic terminal sequence
(varATS) [24]. This assay is highly sensitive and hence
useful for the detection of low-density malaria infections
that are usually found in low-transmission settings. Posi-
tive samples will be screened for molecular markers of
drug resistance, namely the Pfcrt-76 and Pfmdr1-86 gene
polymorphisms, using the established high-resolution
melting protocols [25].
Data collection, management, and analysis
Data from the census of the villages and measured weights
will serve as the platform for trial activities and will be
stored in a retrievable format in a Microsoft Access
database (Microsoft Corp., Redmond, WA, USA) set up
on electronic tablets. Information on the confirmed case
will be used to identify the compound of the index case
and generate a list of persons for treatment and follow-up.
In the control villages, forms will be generated that are
based on the compound of the malaria case for persons
from whom to collect a blood sample for parasite detec-
tion. Completed forms will be double-entered into an
OpenClinica database (OpenClinica LLC, Waltham MA,
USA). Results derived from the analysis of samples from
the prevalence surveys will be linked to the main trial
database for the analysis. All staff involved in the trial will
be trained on their specific tasks.
The primary endpoint, P. falciparum prevalence, de-
fined as the proportion of sampled residents carrying
parasites detectable by varATS PCR, will be compared
between study arms using generalized estimating equa-
tions to account for within-cluster correlations.
Random-effects multivariable logistic regression models
will be used to analyze binary outcomes, and mixed lin-
ear regression will be used for normally distributed
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continuous outcomes. An interim analysis of results is
not planned, and the analysis plan will be produced and
agreed on before the close of the trial database.
For the cost-effectiveness analysis, we will describe the
costing of the trial and estimate the costs of implement-
ing similar interventions at a programmatic scale. This
takes into account the existing infrastructure and a pro-
jection of any additional resources required to be able to
deliver the interventions outside a trial setting and inte-
grate them into the existing health system, including the
National Malaria Control Program and community-
based health services. We will run a series of sensitivity
analyses, taking into account various possible inputs and
processes for the interventions’ scaling-up (Fig. 4).
Quality management
A data and safety monitoring board (DSMB), independ-
ent of the sponsor, will be appointed to advise the spon-
sor and investigators on safety issues in the trial. During
the trial, study nurses and VHWs will be trained to
check and report all events associated with treatment
with DP. All adverse or serious adverse events will be re-
ported to the local ethics committee and the DSMB,
based on reporting schedules stated in the protocol
(Additional file 1).
The study will apply a transdisciplinary approach in
the conduct of the trial with a team comprising epidemi-
ologists, social scientists, health systems researchers, and
health economists. A prototype for intervention, de-
signed by the trial team, will be tested and adapted in
the first year using feedback from researchers, relevant
community stakeholders, health service providers, and
policy makers according to their knowledge and experi-
ence. Perceptions, understanding, and messages during
the implementation stage will be monitored systematic-
ally with implementation problems dialogically tackled
by the trial team.
The trial is implemented through the Gambian health
system, including VHWs supervised by community
health nurses on routine tasks and by study staff on
trial-specific procedures. Study nurses will be based at
selected health facilities and will rely on the active par-
ticipation of identified key stakeholders in each interven-
tion community, patients with malaria, and their
compound members for implementation and feedback.
Confidentiality of trial data and result dissemination
Information on study participants will remain confiden-
tial. Unique identifiers will be used on case report forms
(CRFs) and filter papers; CRFs will be kept in locked
files; and electronic data on tablets will have password
securities accessible only to authorized study team mem-
bers. All identifiable information will be delinked from
data before being transferred to the study database. The
results of the trial will be shared with The Gambia’s
Ministry of Health and Social Welfare through the
National Malaria Control Program and with the partici-
pating communities.
Discussion
Malaria morbidity and mortality have declined below
levels previously thought unachievable in sub-Saharan
Africa [14]. This was made possible by the increased ac-
cess to effective interventions such as LLINs and ACTs.
Despite this, the risk of malaria transmission persists
owing to a large human reservoir of infection that consists
mainly of asymptomatic infections [26]. Therefore, redu-
cing the prevalence of infections is required to sustain the
current gains and eventual elimination of the disease.
Countries that have eliminated malaria have been suc-
cessful mainly by controlling the mosquito vector and by
MDA [27, 28]. Although there is renewed interest in use
of MDAs, contemporary reviews on their utility for mal-
aria elimination raises questions regarding their cost-
effectiveness, sustainability, the increased drug pressure,
and the potential for the emergence of drug-resistant par-
asites [3, 27]. This has led to proposing focused ap-
proaches such as mass screening and treatment, although
available field diagnostic tests are not sufficiently sensitive
to detect low-density infections [11]. These programs re-
quire a huge commitment and effort by the health system,
and high coverage of these interventions is difficult to sus-
tain without engagement of the local community.
Community engagement and participation has played
a critical role in malaria control [29, 30] and elimination
[31]. However, it is challenging to maintain enthusiasm
and participation when the perception of the risk of dis-
ease is declining. Studies to identify and evaluate ways to
engage communities to ensure sustained and high cover-
age of community-targeted interventions are needed.
The use of an iterative investigatory approach into the
evolving local sociocultural, behavioral, and practical is-
sues that affect malaria prevention and treatment has
been proposed [16], and this could be applied in the
context of a malaria elimination program targeting
asymptomatic infections [32, 33].
In this trial, we build on the already established con-
cept of passive case detection to target for treatment in-
dividuals around the index case, and this will be done
with the active involvement of patients, their family
members, and existing community organizations to
optimize adherence. The treatment for compound mem-
bers will be delivered either by the patients themselves
or by the local VHW. Distribution within the compound
will be implemented by the VHW or VC trained by the
study team, and the process will be overseen by the head
of the compound. The study team, via the VHW or VC,
will monitor treatment compliance. In The Gambia, the
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compound is a recognizable spatial unit and a cluster of
persons with similar exposure to mosquito bites and
treatment-seeking behavior [34]. It is assumed that the
systematic treatment of both cases and compound
contacts should reduce or eliminate the reservoir of
infection and hence decrease or interrupt malaria trans-
mission. Formative research will provide precious informa-
tion on the best approach to optimizing the intervention by
focusing on “what” (messages, form, and content), “how”
(tools and strategies), “when and where”, and “who” (insti-
tutions and individuals). The study is designed with the goal
of developing a model that can be rapidly operationalized
by national malaria control programs.
Trial status
The current protocol is version 3.0 (15 February 2017).
Field activities for the exploratory phase were conducted
between August and December 2016. The implementa-
tion stage ran from August 2017 to January 2018. The
end of the study survey was planned in December 2017.
Trial results are expected in July 2018. Trial is ongoing.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 59 kb)
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